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2Graphical Abstract32
Ion channel blockers inhibit T lymphocyte proliferation at low mitogen concentrations. This33
effect diminishes upon using higher mitogen concentrations, but the antiproliferative effect can34
be recovered by combining ion channel blockers with other immunopharmacological agents such35
as the mTOR inhibitor rapamycin.36
Abstract37
Ion channels are crucially important for the activation and proliferation of T lymphocytes,38
and thus, for the function of the immune system. Previous studies on the effects of channel39
blockers on T cell proliferation reported variable effectiveness due to differing experimental40
systems. Therefore our aim was to investigate how the strength of the mitogenic stimulation41
influences the efficiency of cation channel blockers in inhibiting activation, cytokine secretion42
and proliferation of T cells under standardized conditions.43
Human peripheral blood lymphocytes were activated via monoclonal antibodies targeting44
the TCR-CD3 complex and the co-stimulator CD28. We applied the blockers of Kv1.345
(Anuroctoxin), KCa3.1 (TRAM-34) and CRAC (2-Apb) channels of T cells either alone or in46
combination with rapamycin, the inhibitor of the mammalian target of rapamycin (mTOR). Five47
3days after the stimulation ELISA and flow cytometric measurements were performed to48
determine IL-10 and IFN-γ secretion, cellular viability and proliferation.49
Our results showed that ion channel blockers and rapamycin inhibit IL-10 and IFN-γ50
secretion and cell division in a dose-dependent manner. Simultaneous application of the blockers51
for each channel along with rapamycin was the most effective, indicating synergy among the52
various activation pathways. Upon increasing the extent of mitogenic stimulation the anti-53
proliferative effect of the ion channel blockers diminished. This phenomenon was unknown to54
date but may be important in understanding the fine-tuning of T cell activation.55
1. Introduction56
T lymphocytes are highly potent cells of the adaptive immune system and are crucially57
important in the maintenance of immunological homeostasis. Rapid and specific activation58
through the TCR and its co-receptors CD4 and/or CD8 lead to the recruitment of numerous down-59
stream pathways, that ultimately result in T cell activation and proliferation, and subsequently60
lead to the differentiation into effector or memory cells [1,2].61
Physiological T cell activation occurs upon contact with professional antigen presenting62
cells. The consequence of antigen presentation depends on the age and the stage of differentiation63
of the T cell, and also on the intensity and the duration of the stimulus [3]. It is well established64
that the co-localization of different signaling molecules forms an immunological synapse, which65
enhances the subsequent cellular response [4,5]. The molecules forming the immunological66
synapse on the T cell side involve the TCR-CD3 complex together with co-activator molecules67
such as CD28 [6], CD40 ligand [7] or the IL-2R [8].68
Considering that the underlying mechanisms of lymphocyte stimulation are necessary for69
understanding the ensuing immune responses, various methods were designed to mimic in vivo70
activation pathways. These methods include monoclonal antibodies targeting the TCR-CD371
4complex and other co-activator molecules [9,10]; cross linking of cell surface glycoproteins via72
mitogenic lectins such as PHA [11] and bypassing T cell Ca2+-signaling by ionomycin and the73
diacylglycerol-analog PMA [12]. As these methods are not epitope-specific, they result in a high74
degree of cytokine secretion, such as the anti-inflammatory cytokine IL-10 and the inflammatory75
cytokine IFN-γ, and eventually in T cell activation and mitosis [13]. The pro-inflammatory IFN-76
γ is secreted by a wide array of cells, such as natural killer cells, Th1 CD4 and CD8 cytotoxic T77
cells and even macrophages. On the other hand, anti-inflammatory IL-10 is mainly secreted by78
Th2 T cells and regulatory CD4+/CD25+/FoxP3+ Treg cells [14].79
Ion channels are important in cellular signaling, even in electrically non-excitable cells,80
such as immune cells. Since 1984, when electric signals from lymphocytes were first recorded81
[15,16], it has been suggested that ion channels are involved in the regulation of the immune82
system. To date numerous ion channels have been discovered in T cells (summarized in [17,18]):83
the Ca2+-release activated Ca2+ channel (CRAC) [19]; the Shaker-type voltage-gated K+ channel84
Kv1.3 [20], the Ca2+-activated K+ channel, KCa3.1, formerly known as IKCa1 [21,22]; the non-85
selective TRPM7, that is suggested to be involved in the magnesium homeostasis of the cell;86
TRPM2, important in T cell activation and proliferation [23], and finally the swelling-activated87
chloride channel Clswell, encoded by the SWELL 1 gene [14,24]. As CRAC, Kv1.3 and KCa3.188
channels co-localize in the immune synapse and are up-regulated in different T-cell subtypes89
[5,25], it is widely accepted that these channels are indispensable early factors in the Ca2+-90
dependent activation pathways of the T cell [26]. Increase in [Ca]i may activate pathways91
involving the calcium-calmodulin complex and other secondary messenger molecules such as92
calcineurin. This phosphatase dephosphorylates the nuclear factor of activated T-cells (NFAT),93
allowing its dimerization and nuclear translocation. This transcription factor can then bind to the94
promoter region of target genes involved in cytokine production and proliferation of T95
lymphocytes [20,26].96
5As ion channels are key players in T lymphocyte activation, their blockade can decrease97
the array of pathological immune responses in vivo. Kv1.3 is an excellent candidate for98
immunotherapy, as it is expressed predominantly in astrocytes, T lymphocytes and99
oligodendrocytes [27] in contrast to CRAC and KCa3.1 channels, that are widely distributed and100
thus their blockers may have more side effects. Successful experimental trials employing Kv1.3101
blockers have already been performed in animal models of autoimmune diseases such as multiple102
sclerosis [25], type 1 diabetes mellitus or rheumatoid arthritis [28].103
Besides the Ca2+-dependent mechanisms, other signaling pathways also participate in T104
cell activation that do not involve NFAT signaling. Such pathways include the mammalian target105
of rapamycin (mTOR), which contributes to the activation of both translational and metabolic106
pathways, and allows DNA synthesis [29,30]. The mTOR can be blocked indirectly using107
rapamycin (also known as sirolimus), which inhibits the FK506 binding protein (FKBP12), that108
interacts with mTOR. Rapamycin is a highly effective immunosuppressive drug, that is currently109
widely used in the treatment of kidney graft rejection or graft versus host disease [31].110
The anti-proliferative effects of different ion channel blockers on T cells have already111
been described in a number of experiments and reviews. However, there is an obvious variability112
in the results of previous studies related to this topic. For example, the average blocker113
concentration necessary for 50% inhibition of cell proliferation ranged from 1×Kd concentration114
to 1000×Kd in case of Kv1.3 channel blockers, or from 1.5×Kd to 275 × Kd in the case of the115
KCa3.1-blocker TRAM-34, where Kd is the drug concentration required to block half of the116
relevant channels [25,32-35]. Moreover, TRAM-34 inhibition alone had no effect on the117
proliferation of mixed T cell populations [36]. The underlying mechanism responsible for this118
variability has not been systematically addressed before, but must be largely due to the different119
methods of T cell stimulation and different doses of mitogens applied in these studies. Therefore120
our aim was to elucidate this phenomenon by comparing the anti-proliferative effects of ion121
6channel blockers and rapamycin on lymphocytes cultured and activated under identical122
experimental conditions. Moreover, considering our results at various mitogen concentrations,123
we propose a theory to explain the underlying mechanisms of our observations.124
125
2. Materials and Methods126
2.1 Isolation and cultivation of mononuclear cells127
PBMCs were isolated from heparinized (heparin from TEVA Pharmaceutical Industries128
Ltd., Debrecen, Hungary) peripheral blood of healthy volunteers. First the blood was diluted with129
Hanks’ Balanced Salt Solution (HBSS; from Sigma-Aldrich Co., Saint Louis, MO, USA) in 1:1130
ratio, and then centrifuged using the Ficoll-Hypaque density gradient (GE Healthcare Life131
Sciences, Little Chalfont, UK) at 1400 rpm for 30 minutes at room temperature. Next, the opaque132
layer of mononuclear cells was collected and washed two times with 50 ml HBSS. In n=4133
experiments we used purified CD3+ T lymphocytes obtained by negative selection using134
RosetteSep™ (Stem Cell Technologies™, Vancouver, Canada) technique according to the135
description in the manual. We did not find significant differences between CD3+ T cells and136
PBMCs regarding the extent of proliferation (p=0.785) or in the proliferation-inhibiting effect of137
Antx at Kd (p=0.667) and 10Kd (p=0.333) concentrations. Therefore, we used the PBMC138
population in the majority of our experiments.139
Following carboxifluorescein succinimidyl ester staining (CFSE stining, see below) and140
activation, cells were cultured in 24 or 96 well plates at a cell density of 106 cells/ml in standard141
RMPI-1640 medium (Sigma-Aldrich Co., Saint Louis, MO, USA) containing 15% HEPES buffer142
(Sigma-Aldrich Co., Saint Louis, MO, USA) at 37°C in humid atmosphere with 5% CO2. In143
every experiment all plates were incubated for 5 days and were supplemented with fresh culture144
7medium on day 3. After harvesting, the cells underwent pripodium iodide (PI) staining and145
subsequent FACS analysis.146
147
2.2 CFSE dilution assay and PI staining148
We applied the CFSE dilution essay, originally described by Lyons et al [37-39], to149
measure the rate of proliferation. The staining procedure briefly was the following: the150
membrane-permeable, but non-fluorescent carboxyfluorescein diacetate succinimidyl ester151
(CFDA-SE) binds to structural proteins within the cell, and is subsequently cleaved by152
nonspecific esterases to become the membrane non-permeable and fluorescent molecule CFSE.153
Upon cell division, the amount of CFSE is gradually halved in the daughter cells, thus the number154
of division cycles the cells have undergone can be determined. In our case, the lymphocytes155
divided usually every 24-48 hours, leading to 4-6 measurable cycles at the end of our156
experiments.157
The final concentration of CFDA-SE (CellTrace™ CFSE Cell Proliferation Kit, Life158
Technologies Co., Waltham, MA, USA) in our experiments was 1µM that provided a 100-to-159
1000-fold increase in the fluorescence intensity of the measured cells over the autofluorescence160
of unstained cells. After adding CFDA-SE, we incubated the PBMCs or T lymphocytes for 15161
min at room temperature, then for 20 min at 37°C. Lastly, the cells were washed once with162
phosphate buffer solution (PBS). We took care that the CFSE-stained cells remained hidden from163
excess light during our experiments. This CFSE staining can be ultimately recorded by flow164
cytometry.165
PI staining was performed at the end of the 5-day incubation period. Therefore, we166
harvested and washed the cells once using HBSS, then added 1 µl PI to the cell suspension. Cells167
8were mixed gently with PI and then incubated in the dark for 5 minutes at room temperature. The168
flow cytometer settings were adjusted to a negative control tube containing unstained cells. PI169
fluorescence intensity was measured in the red channel, because samples were co-stained with170
CFSE.171
2.3 Selective stimulation of T lymphocytes172
At the beginning of the present study, we performed preliminary experiments regarding173
our preferred method of stimulation. Four widely used and well-known lymphocyte stimulation174
techniques were compared using CFSE dilution assay on PBMCs: PHA stimulation [11]; PMA175
combined with ionomycin [12]; soluble anti-CD3 antibody alone and in combination with anti-176
CD28 [9,10]. Moreover, we measured whole-cell K+ currents and current density on177
representative populations of the stimulated T cells. We found the anti-CD3 and anti-CD28178
stimulation was most reproducible (data not shown) and thus, we used this approach in our179
experiments detailed in this article.180
We applied 200 nM – 3 µM soluble anti-CD3 antibodies combined with a constant181
amount of 1 µg/ml soluble mouse anti-human CD28 (Sigma-Aldrich Co., Saint Louis, MO, USA)182
in n=8 experiments for specific T cell stimulation in the PBMC and lymphocyte cultures. We183
enhanced the rate of stimulation by adding the soluble antibodies to the bottom of the culture184
well, left it to bind to the plate surface for 30 minutes at room temperature, then cells were added185
to the wells in culture medium suspension. In n=8 experiments we used superparamagnetic bead-186
conjugated anti-CD3 and anti-CD28 monoclonal antibodies (Life Technologies Co., Waltham,187
MA, USA), which we found more user-friendly than the soluble antibodies. The pairwise188
comparison of soluble mitogens and bead-mediated stimulation Student’s t-test showed no189
significant difference between the divided cell populations with the two methods of stimulation190
(p=0.336). The beads are also known to provide adequate cross-linking thus inducing a relatively191
9high level of activation [10], in contrast to stimulation with soluble anti-CD3 and anti-CD28, that192
resulted in a higher amount of variability in our measurements [9]. The bead:cell ratio in these193
cases was 1:200 - 1:1 (see Results).194
195
2.4 Application of ion channel blockers and rapamycin196
To block the Kv1.3 channel we used the peptide-type toxin Antx [40]. KCa3.1 channels197
in were blocked using TRAM-34 (Sigma-Aldrich Co., Saint Louis, MO, USA) [34] and the198
CRAC channels were inhibited by 2-Apb (Sigma-Aldrich Co., Saint Louis, MO, USA) [41]. We199
used the ion channel blockers at two concentrations: the lower was equal to the dissociation200
constant, or 1×Kd, of ion channel inhibition of the blockers and the higher was 10 times the Kd201
(10×Kd). In the case of Antx, we used 500 pM (1×Kd) and 5 nM [40]. In the case of 2-Apb the202
Kd for lymphocytes is 5 μM, and the other concentration used was 50 μM. Finally, the KCa3.1203
blocker TRAM-34 was used in 20 nM (1×Kd) and 200 nM concentrations. In the case of204
rapamycin the lowest concnetration reported in the literature [42,43] to inhibit T cell proliferation205
by 50% (1xIC50 =20 pM) was used as the lower dose and 200 pM (10×IC50) was used as the206
higher dose.207
2.5 Flow cytometry experiments208
The flow cytometry measurements were performed on a BD FACScan™ and Facs209
Array™ flow cytometers. We measured the light scatters, namely the forward scatter (FSC) and210
side scatter (SSC) and the fluorescence intensity on green and red channels. Gate setting for211
lymphocytes is shown in Fig. 1A, and the gating of viable cells is represented on Fig. 2A and B.212
The sheath fluid consisted of 1x PBS. Lymphocytes were selected from mixed cell populations213
of PBMC by their light scatter profile on FACS analysis. Cell proliferation was measured based214
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on the declining CFSE intensity in the green channel (Fig. 1B.). Division index (DI) was used215
was the the indicator of proliferation and was calculated by this formula216
= /217
where k is the division cycle number (i.e. generation number) of cells, and Ak is the cell218
number in the kth division cycle according to Fig. 1B.219
2.6 Measurement of cytokine concentration220
Culture supernatants of human peripheral blood mononuclear cells (n=3) were harvested five221
days after application of mitogens and ion channel blockers, and the concentration of IL-10 and222
IFN-γ was measured using OptEIA kits (BD Biosciences, Franklin Lakes, NJ, USA), according223
to manufacturer's instructions, using duplicates.224
2.7 Data evaluation and statistics225
Flow cytometric data were collected using BD CellQuest™ 12.1. For data analysis we226
used the freeware program Cyflogic 1.2.1. The analyzed data was exported to Microsoft Office227
Excel™ 2007. For statistical evaluation of our results we used the program SigmaPlot™ 12.0,228
where we applied one-way ANOVA test and as post hoc analysis, Holm-Sidak test versus the229
positive control cell population. We marked the level of significance with * if p was <0.05, with230
**, if p was <0.01, and with ***, if p was <0.001. Data are represented as mean ±S.E.M.231
232
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3. Results233
3.1 Dose-dependence of mitogen-induced proliferation234
As stated in the introduction, our first step was to achieve multiple levels of selective T235
lymphocyte stimulation using anti-CD3 and anti-CD28 monoclonal antibodies. Fig. 1. shows that236
comparing the division indices (DI) of stimulated PBMC populations 5 days following mitogen237
stimulus, four levels of the mitogen effect could be distinguished: low concentration (200 ng/ml238
or 1 bead:200 cells) of the mitogen led to a relatively low amount of proliferation, while the239
medium (500 ng/ml or 1 bead:50 cells), high (1 µg/ml or 1 bead:10 cells) and very high240
concentrations (3 µg/ml or 1 bead:1 cells) resulted, as expected, in markedly higher rates of cell241
division. The mean DI are 30.6 ± 4.8%, 60.8 ± 4.5%, 72.7 ± 1.5% and 85.3 ± 2.4%, respectively.242
Pairwise comparison of the observed proliferation rates indicated a significant increase with each243
subsequent increase in mitogen concentration (p=0.0036; p=0.044; p=0.0042, respectively).244
12
Figure 1. Cell proliferation at different mitogen concentrations. A) The left and middle dot245
plots show stimulated PBMC populations stimulated by 1 µg/ml anti-CD3 and anti-CD28246
monoclonal antibodies on day 0 and day 5, respectively. Solid black line polygons indicate the247
position of the gates. Activated T cells on day 5 (middle) having higher light scatter properties248
and mainly dead cells outside the gate are clearly distinguishable. The dot plot on the right shows249
the FSC/ Fluorescence intensity of the same population as on the middle dot plot, where the250
gradual decline in the CFSE intensity as a consequence of cell division can be observed. B) The251
fluorescence intensity histogram shows CFSE fluorescence intensity obtained from the gated252
population of the dot plot on the right in panel A. The marker above the histogram indicates the253
divided and the undivided cell populations, and the ratio of divided cells to all gated cells was254
calculated yielding the division index (DI, see Materials and Methods). C) DI of the cells255
stimulated by anti-CD3 and anti-CD28 at various mitogen concentrations (low: 200 ng/ml or 1256
bead:200 cells; medium: 500 ng/ml or 1 bead:50 cells; high: 1 µg/ml or 1 bead:10 cells; and very257
high concentration: 3 µg/ml or 1 bead:1 cells). The DIs of these populations are shown in Fig 2258
as positive controls (Pos.) and the DI of inhibitor treatments were normalized to this data.259
3.2 Ion channel blockers and rapamycin alone and in combination inhibit lymphocyte260
proliferation261
The effect of ion channel inhibitors on cell proliferation was tested at a concentration262
corresponding to the dissociation constant of the drug on the relevant channel (1×Kd) and at ten263
times higher concentration (10×Kd). Rapamycin was used at the lowest IC50 obtained from the264
relevant literature [42,43], and at ten times higher concentration. Figs. 2A-2D show265
representative fluorescence histograms of the CFSE dilution assay recorded in the absence or in266
the presence of the blockers in two concentrations. The markedly reduced peaks of the gray-267
shaded histogram relative to the control light-gray line in Fig. 2A qualitatively show that the268
Kv1.3 K+ channel blocker anuroctoxin (Antx) at 10×Kd concentration inhibited proliferation269
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when the cells were stimulated at low mitogen concentration. Quantitative analysis using270
normalized DIs (Figs 2E and F) showed that Antx at 1×Kd and 10×Kd concentration inhibited271
proliferation at low (p=0.004, p<0.001, respectively), but not at very high (p=0.930) mitogen272
concentration. The nearly superimposable fluorescence histograms in Fig. 2B show that the273
KCa3.1 inhibitor TRAM-34, regardless of its concentration, caused only a minor reduction of274
the proliferation of T cells stimulated by low mitogen concentration. The statistical analysis of275
the DIs (Figs 2E and F) showed that TRAM-34 failed to inhibit cell proliferation both at 1×Kd276
and at 10×Kd concentrations regardless of the mitogen concentration used (at 10×Kd TRAM-34277
concentration p= 0.489 and p=0.993 for low and very high mitogen concentrations, respectively).278
The gray-shaded histogram in Fig. 2C shows qualitatively that at low mitogen stimulation the279
CRAC channel modulator, 2-Aminoethoxydiphenyl borate (2-Apb) applied at 10×Kd blocker280
concentration inhibited cell proliferation whereas 1×Kd blocker concentration was ineffective.281
This was confirmed by statistical analysis in Fig. 2E (p=0.694 for 1×Kd and p<0.001 for 10×Kd).282
Fig. 2F shows that at very high mitogen concertation 2-Apb did not inhibit T cell proliferation283
even at 10Kd concentration.284
The representative histograms in Fig. 2D shows that the mTOR inhibitor rapamycin,285
applied at both 1IC50 and 10IC50 concentrations markedly inhibits the proliferation of T cells286
stimulated with low mitogen concertation. This effect was confirmed by the statistical analysis287
shown in Fig 2E (1 IC50: p=0.003; 10IC50: p<0.001). As opposed to the ion channel blockers288
Antx and 2-Apb, rapamycin alone inhibited proliferation even at very high mitogen concentration289
(p<0.001) both at 1IC50 and 10IC50 doses. As shown in Figure 2G, using the combination of290
all ion channel blockers at 10×Kd concentration led to a marked inhibition of cell proliferation291
(p<0.001), which did not differ from the blocking potential of 10 IC50 rapamycin (p=0.113).292
The inhibitory effect of ion channel blockers combined with rapamycin proved to be the most293
effective treatment, resulting in the complete blockage of cell division (p<0.001 compared to294
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control, mean DI=0.163). In the latter case proliferation was not significantly different from the295
negative control group (mean DI=0.110), which was not stimulated by mitogens (p=0.515).296
Data above showed that the Kv1.3 blocker Antx and the CRAC channel blocker 2-Apb297
interfered with T cell proliferation only if cells were stimulated at low mitogen concentration but298
were ineffective if cells were stimulated with very high mitogen concentration. To further explore299
this phenomenon, we measured the normalized DI at varying mitogen concentrations (low,300
medium, high and very high, see above) in the presence of 1×Kd (Fig. 2H left panel) or 10×Kd301
(Fig. 2H right panel) concentrations of Antx. As shown in Fig. 2H right panel a marked inhibition302
of cell division was observed when the combination of low mitogen and 10×Kd blocker303
concentration (black bar) was used (p<0.001). At medium, high and very high mitogen304
concentrations the inhibition of proliferation was not statistically significant as compared to the305
positive control (p=0.089, 0.372 and 0.742, respectively), but a clear decreasing trend is seen in306
the effectiveness of the blockers with increasing mitogen concentration. The same tendency307
could be observed if Antx was applied at 1×Kd concentration (Fig. 2H left panel). The inhibition308
of proliferation was statistically significant only if low mitogen concentration (p=0.004) was309
used whereas at medium, high, and very high mitogen concentrations the inhibition of310
proliferation did not prove to be significant (p=0.365, 0.955 and 0.964 at medium, high and very311
high mitogen concentrations, respectively).312
15
313
314
Figure 2. Effect of ion channel blockers and rapamycin on cell proliferation. A-D) The315
representative fluorescence histograms corresponding to the CFSE dilution assay (see methods)316
show the effect of four inhibitors on T cell proliferation. Light gray lines in the histograms317
 
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indicate the positive control population (Pos.) treated solely with mitogens, black lines and gray318
filled histograms indicate data obtained in the presence of a blocker at 1×Kd and 10×Kd319
concentrations, respectively (A: Antx, 500pM (1×Kd) and 5 nM; B: TRAM-34 (T-34), 20 nM320
(1×Kd) and 200 nM; C: 2-Apb, 5 μM (1×Kd) and 50 μM; D: rapamycin (Rapa), 20 pM (1×IC50)321
and 200 pM (10×IC50)). Cells were stimulated with low mitogen concentration in each case (200322
ng/ml anti-CD3 and 1 µg/ml anti-CD28 or 1 bead:200 cells).  E-F) Proliferation, represented by323
DI (see Figure 1.), at low (Fig. 2E, 200 ng/ml anti-CD3 and 1 µg/ml anti-CD28 or 1 bead:200324
cells) or very high (Fig. 2F, 3 µg/ml and 1 µg/ml anti-CD28 or 1 bead:1 cell) mitogen325
concentrations in the presence of 1×Kd (cross-hatched bars) and 10×Kd (gray) blocker326
concentrations (for concentrations, see above). Neg. indicates the negative control population,327
where cells were not stimulated by mitogens, but were stained with CFSE. The DIs of samples328
treated with different blockers were normalized to the average DI of the Pos. sample. G)329
Comparison of the effectiveness of treatment combinations as compared to the positive control330
(Pos.). During the combined treatments each blocker was applied at its 1×Kd (cross-hatched) or331
10Kd (gray) concentration, data obtained for different mitogen concentrations were pooled for332
the analysis. H) Mitogen-dependence of the inhibition of cell proliferation. The DIs were333
determined in the presence of Antx at 1×Kd (left) or 10×Kd (right), at low (black), medium (dark334
gray), high (gray) and very high (light gray) mitogen concentrations (see legend to Fig. 1). Error335
bars indicate SEM, asterisks indicate significance (* if p was <0.05, with **, if p was <0.01, and336
with ***, if p was <0.001)337
338
3.3 Cell viability is not affected by inhibitors of T cell proliferation339
The reduced proliferation in the presence of the ion channel blockers and rapamycin (see340
above, Fig. 2) might be induced by a decrease in the viability of the cells in the presence of these341
17
compounds. This was tested in the experiments shown in Fig. 3 using a propidium iodide uptake342
assay. The dot-plots in Fig. 3A show the threshold discriminating viable and non-viable cells343
using the combination of forward scatter and PI fluorescence. The corresponding fluorescence344
histograms in Fig 3B show that stimulation of the cells increased the proportion of the viable345
cells. The proportion of viable cells was not altered either by the ion channel blockers or346
rapamycin alone, or in their various combinations regardless of the concentration of the347
compounds (Fig. 3C, 1×Kd: p=0.903, 0.902, 0.652 and 0.508 for Antx, TRAM-34, 2-Apb and348
rapamycin, respectively; or 10×Kd: p=0.871, 0.867, 0.740 and 0.225 for Antx, TRAM-34, 2-Apb349
and rapamycin, respectively; p=0.244 for their combination).350
351
Figure 3. Effect of ion channel blockers and rapamycin on the cellular viability. A) The dot352
plots show the standard gating strategy for propidium iodide (PI) staining. The left panel indicates353
non-stimulated (Neg.), the right panel shows the stimulated population (Pos.) after 5 days of354
incubation with superparamagnetic bead-conjugated anti-CD3 and anti-CD28 monoclonal355
antibodies at 1 bead:1 cells ratio. The horizontal black line indicates the threshold for356
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discriminating live and non-live cells. B) The fluorescence histograms were generated from the357
dot plots shown in A, the bar and the markers indicate the PI negative viable and the PI positive358
non-viable cells in the Neg. (black line) and Pos. (gray fill) samples. C) Viability of the cell359
populations in the presence of inhibitors. The number of PI negative cells in the presence of360
various compounds was normalized to that of the untreated, but activated cells (Pos. sample).361
Cross-hatched and gray bars show data obtained in the presence of 1×Kd and 10×Kd362
concentrations of the indicated compounds alone or in mixtures (T-34: TRAM-34, Rapa:363
rapamycin). Mixtures of ion channel blockers contained each blocker at 1×Kd or 10×Kd (Ion Ch.364
blockers) whereas in the Ion Ch. Blockers+Rapa samples the ion channel blocker mixture is365
supplemented with the corresponding concentrations of rapamycin (1IC50 or 10IC50). Error366
bars indicate SEM.367
368
3.4 Cytokine production of T cells can be reduced by ion channel blockers369
We investigated the effect of channel blockers and rapamycin on the secretion of the anti-370
inflammatory IL-10 and the pro-inflammatory IFN-γ cytokines by ELISA. Increasing the371
mitogen concentration from low to very high induced approximately 4-fold and 10-fold increases372
in secreted IL-10 and IFN-γ levels, respectively (Fig. 4. A and B, Pos.). IFN-γ as well as IL-10373
secretion was significantly inhibited at low mitogen stimulation by all inhibitors and374
combinations at both applied concentrations (Fig. 4. A and B, left panels) (IFN-γ: p<0.001 for375
all inhibitors; IL-10: Antx 1Kd p=0.046, 10Kd p=0.024, TRAM-34 1Kd p=0.048, 10Kd376
p=0.008, 2-Apb 1Kd p=0.039, 10Kd p=0.007, rapamycin 1Kd p=0.009, 10Kd p<0.001, ion377
chann blockers 1Kd p=0.002, 10Kd p<0.001, ion channel blockers together with rapamycin378
1Kd and 10Kd p<0.001). At very high mitogenic stimulation IFN- secretion was inhibited by379
AnTx, rapamycin and combination treatments at 10Kd and by 2-Apb and the ion channel380
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blocker combination at 1Kd (Fig. 4A right panel)( Antx 10Kd p=0.041, 2-Apb 1Kd p=0.049,381
rapamycin 10Kd p<0.001, ion channel blockers 1Kd p=0.002, ion channel blockers together382
with rapamycin p<0.001). IL-10 production was only inhibited by 10Kd 2-Apb, rapamycin and383
combination treatments (Fig 4B right panel) (2-Apb 10Kd: 0.004, rapamycin10Kd:0.002 , ion384
channel blockers p=0.004, ion channel blockers together with rapamycin: p<0.001).385
386
Figure 4. Inhibition of cytokine secretion by ion channel blockers and rapamycin387
A) IFN-γ and B) IL-10 secretion were measured using ELISA (OptEIA kit) at different mitogen388
concentrations, respectively. Left and right panels refer to data obtained at low and very high389
mitogen concentrations. Neg. indicates the unstimulated control cell population whereas Pos.390
indicates the mitogen-stimulated cell population in the absence of ion channel blockers and/or391
20
rapamycin. The blockers are represented at 1Kd (cross-hatched), 10Kd (gray) or in case of392
rapamycin 1IC50 and 10IC50 concentrations, respectively. Error bars indicate SEM, asterisks393
indicate significance (* if p was <0.05, with **, if p was <0.01, and with ***, if p was <0.001),394
and n.d. indicates “not detectable” where values are too low to be shown.395
396
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Discussion397
Altered T cell homeostasis is involved in the pathogenesis of autoimmune diseases such398
as multiple sclerosis [44] and systemic lupus erythematosus [45]. To maximize anti-proliferative399
effects and to reduce potential side effects, immunosuppressive drugs are commonly used in400
combinations [46]. One group of the most promising candidates for future therapy is the family401
of Kv1.3 inhibitors, because this ion channel is found only in a few tissues and it can be inhibited402
selectively [28]. Before applying ion channel blockers in therapy it is crucial to investigate how403
they interact with other immunosuppressive agents. However, original research data about the404
pharmacodynamics of combinations of traditional immunosuppressive and novel drugs such as405
ion channel blockers are scarce and they usually lack functional comparison. Therefore, in our406
recent experiments, we approached this problem from multiple aspects and have found an407
additive interaction between rapamycin and the ion channel blockers when using them in408
combination.409
The effects of ion channel blockers exerted on T cell functions have already been410
described [17]. However, to the best of our knowledge, no data comparing the proliferative411
effects of Kv1.3, KCa3.1 and CRAC channel blockers applied alone or in combination at412
identical experimental conditions are currently available. Moreover, the synergy between the413
effects of ion channel inhibitors and the mTOR inhibitor rapamycin has not been investigated to414
date. In the present study we are the first to describe the mitosis-inhibiting effect of Antx, a high415
affinity scorpion toxin blocker of Kv1.3 [40] both at high (10×Kd) and low (1Kd) concentrations.416
The observed effect of 2-Apb correlated well with past literature, as it was proposed that 2-Apb417
has a bimodal effect. At low blocker concentrations (Kd), 2-Apb promotes Ca2+ signaling, which418
ultimately results in enhanced cell proliferation, whereas at higher concentrations, in our case at419
10×Kd, it effectively inhibits the CRAC channel, ultimately blocking cellular proliferation [47].420
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Even low mitogen concentrations, which corresponded to 1:200 bead:cell ratio produced421
an unexpectedly high amount of polyclonal lymphocyte proliferation, as over 30% of the cells422
have undergone cell division. This phenomenon may be explained by the fact that there is a large423
number of anti-CD3 and anti-CD28 molecules on a single bead, and that lymphocytes form a424
rosette-like structure around beads. Therefore, numerous lymphocytes are activated425
simultaneously by a single bead, and this effect could be further enhanced by autocrine and426
paracrine cytokine secretion of the activated T cells [48,49].427
Our most intriguing finding in this research was that increasing the mitogen concentration428
markedly decreased the anti-proliferative effect of ion channel blockers that ultimately429
completely disappeared when cells were stimulated with very high concentration of the mitogens.430
A possible explanation may be that at low mitogen concentrations the few, initially highly431
localized Ca2+ signals are suppressed by the blocked ion channels in their immediate vicinity432
[50]. However, at very high mitogen concentration when most TCRs are likely to be activated,433
the number of localized signaling loci is sufficiently high so that even a very low fraction of434
unblocked ion channels is sufficient to maintain the downstream activation cascade upon TCR435
activation. Moreover, it is reasonable to assume that lymphocytes redirect their activation436
pathways to other, Ca2+-independent directions. As several intracellular signaling pathways, e.g.437
mTOR activation, do not essentially involve ion channels [29,30], these processes may become438
overly active upon applying very high mitogen concentrations. However, to the best of our439
knowledge no study has ever addressed this question and thus it warrants further experiments.440
At very high mitogen concentrations we could achieve significant blockage of441
proliferation only by using rapamycin or its combination with the ion channel blockers acting on442
a different pathway that ultimately leads to permanent changes in cellular signaling. This may443
indicate that co-treatment of T cells with rapamycin and ion channel blockers may be a more444
feasible therapeutical approach than using these drugs separately.445
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Previous studies have shown that blocking Kv1.3 channels without affecting the KCa3.1446
channels inhibited IFN-γ expression in a subset of T-cells with effector memory phenotye (TEM)447
[51]. Moreover, the blockage of CRAC channels with SKF 96365 decreased both IL-10 and IFN-448
γ production [52]. In line with these studies our data showed that treatment of T-cells with various449
inhibitors (Fig. 4) significantly decreased both anti-inflammatory IL-10 and inflammatory IFN-450
γ cytokine production but only at low mitogenic stimulation. In accordance with the literature451
TRAM-34 strongly suppressed cytokine production despite the fact that it did not not inhibit452
proliferation [14,34]. At very high mitogen concentration the effect of the ion channel blockers453
on cytokine production diminished. Although some of them caused statistically significant454
reductions in cytokine production, these changes are not likely to be biologically relevant as the455
remaining concentration of IFN-γ still remained in the ng/ml range and therefore was sufficient456
to promote cell proliferation, so division rate was unaffected. In contrast, rapamycin and the457
combination treatments applied at 10Kd concentration caused a more robust decrease, which458
was also reflected in the suppressed proliferation of these cells.459
Since IL-10 and IFN-γ levels were affected in a qualitatively similar manner by the460
inhibitors both at low and very high mitogen concentrations, it is safe to assume that these461
treatments did not alter the proportion of T cell subtypes specifically (i.e. Th1 CD4 and CD8462
cytotoxic T cells vs. Th2 T cells and regulatory CD4+/CD25+/FoxP3+ Treg cells), but rather were463
affecting globally the entire T cell population.464
In summary, the greatest level of inhibition of T-cell proliferation and the production of465
selected cytokines could be achieved by rapamycin, and this effect could be further potentiated466
by using it in combination with cation channel blockers. This may indicate an additive effect of467
Ca2+-dependent and Ca2+-independent inhibitory mechanisms involved in T-cell activation.468
Finally, we found that upon increasing the concentration of the mitogenic antibodies, the anti-469
proliferative effect of ion channel blockers faded. This phenomenon can be due to a yet unknown470
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mechanism in intracellular signaling of activated T cells, which is to be elucidated in the future.471
The increased in vitro antiproliferative potentcy of rapamycin and ion channel blocker472
combination presented in this study urges for in vivo experiments whereby the therapeutic benefit473
of the combined treatment can be assesed.474
475
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